قم بالتسجيل لخلق تنبيهات للأدوات الاستثمارية
الأحداث الاقتصادية والمحتوى الخاص بالمؤلفين الذين تتابعهم
تسجيل مجاني هل تملك حساب؟ تسجيل الدخول
اسعار
جميع أنواع الأدوات
- جميع أنواع الأدوات
- مؤشرات
- الأسهم
- الصناديق
- أموال
- سلع
- عملات
- العملات الرقمية
- سندات
- شهادات
برجاء استخدام كلمات أخرى للبحث
احصل على بيانات بريميوم: خصم يصل إلى 50% على InvestingPro احصل على الخصم
(FPHAX) Fidelity Select Pharmaceuticals Portfolio
إضافة إلى/حذف من محفظة
أضف محفظة
29.79
+0.41
+1.40%
- تقييم وكالة (مورننغستار):
- المجموع: 1.48B
Fidelity Select Pharmaceuticals Port
29.79
+0.41
+1.40%
- عام
- الرسم البياني
- تقني
- المنتدى
- نظرة عامة
- بيانات الشركة
- بيانات تاريخية
- الأدوات المملوكة
نظرة عامة - FPHAX
تجد في هذه الصفحة تعريفًا تفصيليًا لـ Fidelity Select Pharmaceuticals Portfolio. تعرف على أهم أعضاء الكادر الإداري لـFPHAX وإجمالي أصولها واستراتيجيتها الاستثمارية وبيانات الاتصال بها، فضلاً عن معلومات أخرى.
معلومات الإتصال
العنوان
483 Bay Street
Toronto,ON M5G 2N7
Canada
Toronto,ON M5G 2N7
Canada
الهاتف
416-307-5200
الفاكس
1-800-387-8092
الموقع الإلكتروني
www.institutional.fidelity.com
كبار المسؤولين التنفيذيين
| اسم | العنوان | منذ | حتى |
|---|---|---|---|
| Karim Suwwan de Felipe | Research Analyst/Portfolio Manager | 2017 | الآن |
| السيرة الذاتية | Karim Suwwan de Felipe is a research analyst and portfolio manager in the Equity division at Fidelity Investments. Fidelity Investments is a leading provider of investment management, retirement planning, portfolio guidance, brokerage, benefits outsourcing, and other financial products and services to institutions, financial intermediaries, and individuals. In this role, Mr. Suwwan de Felipe is responsible for covering and providing recommendations on stocks in the global pharmaceutical sector. Additionally, he manages the Fidelity Select Pharmaceuticals Portfolio. Prior to joining Fidelity in 2010, Mr. Suwwan de Felipe was a senior research associate at Citi Investment Research and Analysis. As a member of the biotechnology research team at Citi, he helped formulate recommendations on large and mid-cap biotechnology equities. Previously, Mr. Suwwan de Felipe conducted molecular biology research at CuraGen Corporation, a biotechnology company in Connecticut, and at Yale University’s Department of Therapeutic Radiology. Mr. Suwwan de Felipe earned his bachelor of science degree in molecular biophysics and biochemistry from Yale University, and his doctorate degree with distinction in cellular, molecular, and biophysical studies from Columbia University’s College of Physicians and Surgeons. | ||
| Asher Anolic | Portfolio Manager | 2013 | 2018 |
| السيرة الذاتية | Asher Anolic is co-manager of the VIP Growth Portfolio, which he has managed since July 2017. He also manages other funds. Since joining Fidelity Investments in 2008, Mr. Anolic has worked as a research analyst and portfolio manager. Prior to joining Fidelity Investments in 2008, Mr. Anolic worked for Bear Stearns as a research analyst. | ||
| Andrew Oh | Equity Research Analyst | 2006 | 2013 |
| السيرة الذاتية | Oh joined Fidelity Investments in 2006 as an equity research analyst. Prior to Fidelity, he was director and senior pharmaceuticals analyst for Leernik Swann & Company in New York. From 2001 to 2004, he was senior equity research associate following the U.S. large cap pharmaceuticals sector for JP Morgan Chase in New York. | ||
| Harlan P. Carere | Portfolio Manager | 2005 | 2007 |
| السيرة الذاتية | Carere is a portfolio manager of Fidelity Investments. He joined Fidelity International Limited in London in 2000 as an equity research analyst following the technology sector. He subsequently served as technology sector leader in the London office. Prior to joining the firm, he was an equity analyst for Berman Capital. | ||
| Ian Gutterman | Portfolio Manager | 2005 | 2005 |
| السيرة الذاتية | Gutterman is a portfolio manager with Fidelity Investments, his employer since 1999. Prior to joining the firm, he was a treasury analyst with MT Bank from 1995 to 1997. | ||
| Gavin Baker | Sector Leader | 2002 | 2005 |
| السيرة الذاتية | Baker joined Fidelity in 1999 as an equity research analyst following companies in the cement and building materials industries. He subsequently followed the semiconductor industry. In 2002, Baker began following the pharmaceutical sector, and managed Fidelity Select Pharmaceuticals Portfolio from 2002 to 2005. He then started following large- cap consumer stocks before assuming — in 2006 —the role of diversified analyst working with the large– cap growth group. Baker most recently began serving as sector leader of the telecom and utilities equity research group. | ||
| Yolanda S. Strock | equity analyst/portfolio Manager | 2001 | 2002 |
| السيرة الذاتية | Yolanda Strock joined Fidelity in 1997 where she is the sector leader of the Health Care Equity Resesarch group. She began managing Fidelity Select Biotechnology Portfolio in February 2000, and assumed her other fund management responsibilities and role of sector leader in June 2000. Yolanda has an MBA in Finance from the Fuqua School of Business at Duke University, a BSc in Marketing from the Wharton School of Business and a BA in economics from the University of Pennsylvania. | ||
اكتب رأيك عن Fidelity Select Pharmaceuticals Portfolio
هل أنت واثق من رغبتك في حذف هذا الرسم البياني؟
احذف إلغاء
هل تريد إستبدال الرسم البياني المرفق برسم بياني جديد؟
إستبدال إلغاء
التعليمات لكتابة التعليقات
إضافة رسم بياني إلى تعليق
تأكيد الحظر
هل أنت تريك بالتأكيد الحظر %USER_NAME%؟
إن قيامك بهذا يعني أنك و%USER_NAME% لن تكونا قادرين على رؤية مشاركات الأخرى على Investing.com.
لقد تم إضافة %USER_NAME% بنجاح إلى قائمة الحظر
بما أنك قد قمت برفع الحظر للتو عن هذا الشخص، فإنه يتوجب عليك الإنتظار 48 ساعة قبل أن تتمكن من تجديد الحظر.
قم بالإبلاغ عن هذا التعليق
أخبرنا كيف تشعر حيال هذا التعليق
تم الإبلاغ عن التعليق
شكرا جزيلا
تم إرسال تقريرك إلى مشرفينا لمراجعته